ARWR
Arrowhead Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +4.7% ·
share flow -3.1% ·
net new positions +5.3%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 25.13K | $1.54M | n/a | n/a |
| Q2 2026 | 133 | +6 | 82.38M | $6.30B | +14 | −7 |
| Q1 2026 | 129 | +9 | 82.68M | $4.92B | +14 | −6 |
| Q4 2025 | 119 | +2 | 83.16M | $5.52B | +3 | n/a |
| Q3 2025 | 18 | 0 | 61.93M | $2.14B | +1 | −2 |
| Q2 2025 | 16 | +2 | 54.75M | $865.08M | +2 | n/a |
| Q1 2025 | 11 | +1 | 14.99M | $191.04M | +1 | n/a |
| Q4 2024 | 10 | -1 | 13.46M | $253.12M | +1 | −2 |
| Q3 2024 | 10 | +1 | 7.88M | $152.69M | +1 | n/a |
| Q2 2024 | 9 | n/a | 6.44M | $167.29M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 8.04M | +10.6% | $655.32M | 0.0% | ▲ Add | 5 | SEC ↗ ×7 |
| 2 | State Street Global Advisors ✦ (passive) | 5.69M | -12.3% | $464.17M | 0.0% | ▼ Trim | 7 | SEC ↗ ×2 |
| 3 | Northern Trust Corp | 1.19M | -28.0% | $97.23M | 0.0% | ▼ Trim | 3 | SEC ↗ ×5 |
| 4 | Dimensional Fund Advisors Lp | 1.18M | +94.2% | $96.31M | 0.0% | ▲ Add | 3 | SEC ↗ ×5 |
| 5 | Bank Of America Corp /De/ | 1.14M | +7.1% | $92.91M | 0.0% | ▲ Add | 3 | SEC ↗ ×7 |
| 6 | T. Rowe Price ✦ | 853.36K | -18.2% | $69.56M | 0.0% | ▼ Trim | 9 | SEC ↗ ×2 |
| 7 | JPMorgan Chase ✦ | 637.40K | -6.7% | $51.77M | 0.0% | ▼ Trim | 4 | SEC ↗ ×6 |
| 8 | Franklin Resources Inc | 462.13K | -0.1% | $37.67M | 0.0% | ▼ Trim | 3 | SEC ↗ ×7 |
| 9 | American Century Companies Inc | 364.21K | -44.1% | $29.69M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Sei Investments Co | 500.62K | +112.8% | $24.74M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 11 | Citigroup Inc | 264.68K | +5.2% | $21.57M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 12 | Legal & General Group Plc | 237.22K | +3.5% | $19.34M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 13 | Raymond James Financial Inc | 169.91K | -6.9% | $13.85M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 14 | Ameriprise Financial Inc | 155.91K | -18.4% | $12.71M | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
| 15 | Bank Of Nova Scotia | 133.81K | -1.6% | $10.91M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Wells Fargo & Company/Mn | 128.79K | -18.7% | $10.50M | 0.0% | ▼ Trim | 3 | SEC ↗ ×7 |
| 17 | New York State Common Retirement… | 95.52K | +128.1% | $7.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Barclays Plc | 86.78K | -24.8% | $7.07M | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
| 19 | Stifel Financial Corp | 73.29K | +526.7% | $5.97M | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
| 20 | Loomis Sayles & Co L P | 65.63K | -61.9% | $5.35M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 21 | Commonwealth Equity Services, Llc | 55.17K | +0.2% | $4.50M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 22 | Us Bancorp \De\ | 38.23K | +10.2% | $3.12M | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
| 23 | Fifth Third Bancorp | 30.53K | -8.7% | $2.49M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 24 | Truist Financial Corp | 14.76K | +40.4% | $1.20M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 25 | Jones Financial Companies Lllp | 8.93K | +208.5% | $704,724 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 26 | Pnc Financial Services Group, Inc. | 7.95K | +8.8% | $648,168 | 0.0% | ▲ Add | 3 | SEC ↗ ×5 |
| 27 | Mml Investors Services, Llc | 5.75K | +79.8% | $468,438 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 28 | Danske Bank A/S | 100 | 0.0% | $8,151 | 0.0% | Held | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 430 holders, 120.06M shares, $7.40B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.00K sh · $173,920
Director · 11.60K sh · $1.01M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology